Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: Potential implications for angiodysplasias?: Correspondence

British Journal of Haematology

Volumn 146, Issue 2, 2009, Pages 220-222

  Bowcock, Stella J ^a   Patrick, Hannah E ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Angiodysplasia; Gastrointestinal bleeding; Hereditary haemorrhagic telangiectasia; Lenalidomide; Thalidomide

Indexed keywords

LENALIDOMIDE; THALIDOMIDE;

AGED; ANGIODYSPLASIA; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; NEUROPATHY; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE;

AGED; ANGIODYSPLASIA; ANGIOGENESIS INHIBITORS; CHRONIC DISEASE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; THALIDOMIDE;

EID: 67649998404     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07730.x     Document Type: Letter

References (7)

1. Bauditz, J. Lochs, H. (2007) Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World Journal of Gastroenterology, 13, 5979 5984. (Pubitemid 350238263)
2. Begbie, M.E., Wallace, G.M.F. Shovlin, C.L. (2003) Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgraduate Medical Journal, 79, 18 24. (Pubitemid 36237873)
3. Dimopoulos, M., Spencer, A., Attal, M., Miles Prince, H., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foa, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J.B. Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New England Journal of Medicine, 357, 2123 2132. (Pubitemid 350146107)
4. Dredge, K., Marriott, J.B., Macdonald, C.D., Man, H.-W., Chen, R., Muller, G.W., Stirling, D. Dalgleish, A.G. (2002) Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer, 8710, 1166 1172. (Pubitemid 35418112)
5. Dredge, K., Horsfall, R., Robinson, S.P., Zhang, L.H., Lu, L., Tang, Y., Shirley, M.A., Muller, G., Schafer, P., Stirling, D., Dalgleish, A.G. Bartlett, J.B. (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research, 69, 56 63. (Pubitemid 40410468)
6. Galustian, C. Dalgleish, A. (2009) Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opinion on Pharmacotherapy., 10, 125 133.
7. Heidt, J., Langers, A.M., van der Meer, F.J. Brouwer, R.E. (2006) Thalidomide as treatment for digestive tract angiodysplasias. Netherlands Journal of Medicine, 64, 425 428. (Pubitemid 46001912)